Lanoconazole - Nihon Nohyaku
Alternative Names: Astat; Latoconazole; M-1100; M-110101; NND-318; TJN-318Latest Information Update: 19 Feb 2021
Price :
$50 *
At a glance
- Originator Nihon Nohyaku
- Developer Maruho; Nihon Nohyaku; Tsumura
- Class Antifungals; Azoles; Imidazoles; Small molecules
- Mechanism of Action Sterol demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Candidiasis; Tinea; Tinea cruris; Tinea pedis
- Discontinued Seborrhoeic dermatitis
Most Recent Events
- 19 Feb 2021 Discontinued - Phase-II for Seborrhoeic dermatitis in Japan (Topical) (Nihon Nohyaku pipeline, February 2021)
- 25 Mar 2020 Maruho completes a clinical trial for lanoconazole in Japan (UMIN000029240)
- 25 Mar 2020 Maruho initiates a clinical trial for lanoconazole in Japan (UMIN000029240)